{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:38:29Z","timestamp":1779215909046,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s44313-025-00105-2","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:57:15Z","timestamp":1763369835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current immunotherapeutic approaches for relapsed\/refractory follicular lymphoma: bispecific antibodies and CAR T-Cell therapies"],"prefix":"10.1007","volume":"60","author":[{"given":"So Yeon","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi-June","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"12","key":"105_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984\u201391. https:\/\/doi.org\/10.1200\/JCO.18.00605.","journal-title":"J Clin Oncol"},{"issue":"9873","key":"105_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2.","journal-title":"Lancet"},{"issue":"S1","key":"105_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5045\/br.2022.2022054","volume":"57","author":"SH Jeong","year":"2022","unstructured":"Jeong SH. Treatment of indolent lymphoma. Blood Res. 2022;57(S1):120\u20139. https:\/\/doi.org\/10.5045\/br.2022.2022054.","journal-title":"Blood Res"},{"issue":"23","key":"105_CR4","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516\u201322. https:\/\/doi.org\/10.1200\/JCO.2014.59.7534.","journal-title":"J Clin Oncol"},{"issue":"14","key":"105_CR5","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, et al. Augment: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188\u201399. https:\/\/doi.org\/10.1200\/JCO.19.00010.","journal-title":"J Clin Oncol"},{"issue":"5","key":"105_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/bloodadvances.2024014053","volume":"9","author":"JR Day","year":"2025","unstructured":"Day JR, Larson MC, Durani U, Koff JL, Wang Y, Habermann TM, et al. Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv. 2025;9(5):1013\u201323. https:\/\/doi.org\/10.1182\/bloodadvances.2024014053.","journal-title":"Blood Adv"},{"issue":"1","key":"105_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91\u2013103. https:\/\/doi.org\/10.1016\/S1470-2045(21)00591-X.","journal-title":"Lancet Oncol"},{"issue":"2","key":"105_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0.","journal-title":"Nat Med"},{"issue":"8","key":"105_CR9","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024;30(8):2199\u2013207. https:\/\/doi.org\/10.1038\/s41591-024-02986-9.","journal-title":"Nat Med"},{"issue":"8","key":"105_CR10","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11(8):e593-605. https:\/\/doi.org\/10.1016\/S2352-3026(24)00166-2.","journal-title":"Lancet Haematol"},{"issue":"7","key":"105_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","volume":"145","author":"LH Sehn","year":"2025","unstructured":"Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies. Blood. 2025;145(7):708\u201319. https:\/\/doi.org\/10.1182\/blood.2024025454.","journal-title":"Blood"},{"issue":"16_suppl","key":"105_CR12","doi-asserted-by":"publisher","first-page":"7049","DOI":"10.1200\/JCO.2025.43.16_suppl.7049","volume":"43","author":"D Jagadeesh","year":"2025","unstructured":"Jagadeesh D, Taszner M, Chong G, Novelli S, Cho S-G, Villasboas JC, et al. Long-term follow-up of the phase 2 ELM-2 study: odronextamab for patients (pts) with relapsed\/refractory (R\/R) follicular lymphoma (FL). J Clin Oncol. 2025;43(16_suppl):7049. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.7049.","journal-title":"J Clin Oncol"},{"issue":"24","key":"105_CR13","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2206913.","journal-title":"N Engl J Med"},{"issue":"12","key":"105_CR14","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38(12):2653\u201362. https:\/\/doi.org\/10.1038\/s41375-024-02410-8.","journal-title":"Leukemia"},{"key":"105_CR15","doi-asserted-by":"crossref","unstructured":"Crochet G, Iacoboni G, Couturier A, Bachy E, Iraola-Truchuelo J, Gastinne T, et al. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood. 2024;144(3):334\u201338.","DOI":"10.1182\/blood.2024024526"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00105-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T22:05:59Z","timestamp":1763417159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00105-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["105"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00105-2","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}